F. R. Ahmann

715 total citations
15 papers, 501 citations indexed

About

F. R. Ahmann is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, F. R. Ahmann has authored 15 papers receiving a total of 501 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in F. R. Ahmann's work include Prostate Cancer Treatment and Research (6 papers), Prostate Cancer Diagnosis and Treatment (4 papers) and Selenium in Biological Systems (2 papers). F. R. Ahmann is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Prostate Cancer Diagnosis and Treatment (4 papers) and Selenium in Biological Systems (2 papers). F. R. Ahmann collaborates with scholars based in United States and France. F. R. Ahmann's co-authors include Donald P. Quick, Peter J. Ell, A Bertrand, Robert H. Reid, A. N. Serafini, R A Lerski, B. David Collier, Katherine Harrison, Frank Grund and A Pecking and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Plastic & Reconstructive Surgery.

In The Last Decade

F. R. Ahmann

14 papers receiving 482 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. R. Ahmann United States 8 247 231 210 126 57 15 501
Ajay Bapna India 10 118 0.5× 80 0.3× 53 0.3× 50 0.4× 42 0.7× 38 363
G. Bower Australia 10 160 0.6× 157 0.7× 110 0.5× 129 1.0× 17 0.3× 13 456
Adalet Demir Türkiye 16 85 0.3× 390 1.7× 86 0.4× 156 1.2× 17 0.3× 36 623
Ouki Yasui Japan 11 130 0.5× 90 0.4× 47 0.2× 171 1.4× 52 0.9× 30 363
Lesley Russell United States 4 134 0.5× 364 1.6× 355 1.7× 120 1.0× 16 0.3× 6 647
C. Martín de Vidales Spain 13 82 0.3× 398 1.7× 46 0.2× 187 1.5× 33 0.6× 38 633
Aya Sugimoto Japan 14 146 0.6× 127 0.5× 39 0.2× 102 0.8× 13 0.2× 46 411
Simona Faraci Italy 12 153 0.6× 143 0.6× 38 0.2× 138 1.1× 15 0.3× 25 452
Ratna Paul Finland 9 50 0.2× 58 0.3× 109 0.5× 46 0.4× 33 0.6× 26 330
Shoji Uetsuji Japan 12 109 0.4× 159 0.7× 49 0.2× 292 2.3× 18 0.3× 37 577

Countries citing papers authored by F. R. Ahmann

Since Specialization
Citations

This map shows the geographic impact of F. R. Ahmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. R. Ahmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. R. Ahmann more than expected).

Fields of papers citing papers by F. R. Ahmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. R. Ahmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. R. Ahmann. The network helps show where F. R. Ahmann may publish in the future.

Co-authorship network of co-authors of F. R. Ahmann

This figure shows the co-authorship network connecting the top 25 collaborators of F. R. Ahmann. A scholar is included among the top collaborators of F. R. Ahmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. R. Ahmann. F. R. Ahmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Dreicer, Robert, Walter M. Stadler, F. R. Ahmann, et al.. (2008). MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Investigational New Drugs. 27(4). 379–386. 58 indexed citations
2.
Ahmann, F. R., et al.. (2005). Coccidioidomycosis of the prostate: a determination of incidence, report of 4 cases, and treatment recommendations. Journal of Infection. 52(1). e19–e25. 14 indexed citations
3.
Agus, David B., David S. Mendelson, Douglas G. McNeel, et al.. (2005). Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in hormone refractory prostate cancer after failure of taxane-based therapy. Journal of Clinical Oncology. 23(16_suppl). 4624–4624. 3 indexed citations
4.
Ahmann, F. R., Stéphane Culine, K. Papadopoulos, et al.. (2005). Phase I trial of irofulven (MGI 114) plus docetaxel in advanced cancers. Journal of Clinical Oncology. 23(16_suppl). 2042–2042. 1 indexed citations
5.
6.
Stratton, M. Suzanne, et al.. (2003). Selenium and prevention of prostate cancer in high-risk men: the Negative Biopsy Study. Anti-Cancer Drugs. 14(8). 589–594. 35 indexed citations
7.
Serafini, A. N., I. Resche, Donald P. Quick, et al.. (1998). Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.. Journal of Clinical Oncology. 16(4). 1574–1581. 310 indexed citations
8.
Dalkin, B.L., et al.. (1997). Prostatic asymmetry as a risk factor for prostatic carcinoma: serial prostate‐specific antigen monitoring and cancer detection. British Journal of Urology. 79(6). 924–926. 4 indexed citations
9.
Catàlona, William J., M’Liss A. Hudson, P.T. Scardino, et al.. (1996). In Reply: Re: Selection of Optimal Prostate Specific Antigen Cutoffs for Early Detection of Prostate Cancer: Receiver Operating Characteristic Curves. The Journal of Urology. 155(4). 1396–1396. 7 indexed citations
10.
Dalkin, Bruce L., F. R. Ahmann, William J. Catàlona, et al.. (1995). Derivation and application of upper limits for prostate specific antigen in men aged 50–74 years with no clinical evidence of prostatic carcinoma. British Journal of Urology. 76(3). 346–350. 9 indexed citations
11.
Ahmann, F. R., et al.. (1995). Prostate‐specific antigen obtained under optimal conditions determines extracapsular adenocarcinoma of the prostate. British Journal of Urology. 75(1). 21–25. 7 indexed citations
12.
13.
Ahmann, F. R.. (1986). Chemohormonal therapy for advanced breast cancer with tamoxifen, adriamycin, and cyclophosphamide (TAC). Plastic & Reconstructive Surgery. 77(5). 862–862. 1 indexed citations
14.
Miller, Thomas P., et al.. (1986). Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): a Southwest Oncology Group Study.. PubMed. 70(9). 1101–4. 14 indexed citations
15.
Ahmann, F. R., et al.. (1983). Mineralocorticoid deficiency associated with aminoglutethimide therapy.. PubMed. 40(8). 538–40. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ajay Bapna Breakdown of academic impact, for papers by G. Bower Breakdown of academic impact, for papers by Adalet Demir Breakdown of academic impact, for papers by Ouki Yasui Breakdown of academic impact, for papers by Lesley Russell Breakdown of academic impact, for papers by C. Martín de Vidales Breakdown of academic impact, for papers by Aya Sugimoto Breakdown of academic impact, for papers by Simona Faraci Breakdown of academic impact, for papers by Ratna Paul Breakdown of academic impact, for papers by Shoji Uetsuji
Rankless by CCL
2026